The UK government is providing funding to bring a software tool used to monitor patients during surgery to market “as soon as possible”, says its developer.
Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.